Risk of Adverse Outcomes Associated With Cardiac Sarcoidosis Diagnostic Schemes.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Myadam Rahul, Crawford Thomas C, Bogun Frank M, Gu Xiaokui, Ellenbogen Kenneth A, Jasti Shilpa, Chicos Alexandru B, Roukoz Henri, Zimetbaum Peter J, Kalbfleisch Steven J, Murgatroyd Francis D, Steckman David A, Rosenfeld Lynda E, Garlitski Ann C, Soejima Kyoko, Bhan Adarsh K, Vedantham Vasanth, Dickfeld Timm-Michael L, De Lurgio David B, Platonov Pyotr G, Zipse Matthew M, Nishiuchi Suguru, Ortman Matthew L, Narasimhan Calambur, Patton Kristen K, Rosenthal David G, Mukerji Siddharth S, Hoogendoorn Jarieke C, Zeppenfeld Katja, Sauer William H, Kron Jordana, Cardiac Sarcoidosis Consortium
Аннотация
OBJECTIVES: This study aims to evaluate the association of different CS diagnostic schemes with adverse outcomes. The diagnostic schemes evaluated were 1993, 2006, and 2017 Japanese criteria and the 2014 Heart Rhythm Society criteria.
METHODS: Data were collected from the Cardiac Sarcoidosis Consortium, an international registry of CS patients. Outcome events were any of the following: all-cause mortality, left ventricular assist device placement, heart transplantation, and appropriate implantable cardioverter-defibrillator therapy. Logistic regression analysis evaluated the association of outcomes with each CS diagnostic scheme.
RESULTS: A total of 587 subjects met the following criteria: 1993 Japanese (n = 310, 52.8%), 2006 Japanese (n = 312, 53.2%), 2014 Heart Rhythm Society (n = 480, 81.8%), and 2017 Japanese (n = 112, 19.1%). Patients who met the 1993 criteria were more likely to experience an event than patients who did not (n = 109 of 310, 35.2% vs n = 59 of 277, 21.3%; OR: 2.00; 95% CI: 1.38-2.90; P < 0.001). Similarly, patients who met the 2006 criteria were more likely to have an event than patients who did not (n = 116 of 312, 37.2% vs n = 52 of 275, 18.9%; OR: 2.54; 95% CI: 1.74-3.71; P < 0.001). There was no statistically significant association between the occurrence of an event and whether a patient met the 2014 or the 2017 criteria (OR: 1.39; 95% CI: 0.85-2.27; P = 0.18 or OR: 1.51; 95% CI: 0.97-2.33; P = 0.067, respectively).
CONCLUSIONS: CS patients who met the 1993 and the 2006 criteria had higher odds of adverse clinical outcomes. Future research is needed to prospectively evaluate existing diagnostic schemes and develop new risk models for this complex disease.